AMGN

AMGEN Inc

460.42

Nov 06 • 3:59 PM ET +0.14 (0.03%)

461.50

Aftermarket • 7:53 PM ET +1.08 (0.23%)

Healthcare Drug Manufacturers - General USA Mega NASD

Nov 05, 9:36 AMAmgen announces large real-world outcomes study showing Repatha cut fatal or nonfatal heart attack risk by 20% versus ezetimibe in more than 500,000 adults with ASCVD

Peers: GILD ABBV BMY MRK PFE JNJ LLY REGN BIIB VRTX

| Held by: VTI VOO QQQ SCHD IVV SPY DIA VTV XLV VIG

Scroll to Statements

Index	DJIA, NDX, S&P 500
Market Cap	249.05B
Enterprise Value	289.86B
Income	9.39B
Sales	38.98B
Book/sh	26.53
Cash/sh	24.38
Dividend Est.	10.07 (2.19%)
Dividend TTM	9.94 (2.16%)
Dividend Ex-Date	Nov 20, 2026
Dividend Gr. 3/5Y	7.05% 8.27%
Payout	66.92%
Employees	31500
IPO	Jun 17, 1983

P/E	26.70
Forward P/E	18.43
PEG	2.61
P/S	6.39
P/B	17.35
P/C	18.88
P/FCF	25.99
EV/EBITDA	15.79
EV/Sales	7.44
Quick Ratio	1.20
Current Ratio	1.48
Debt/Eq	3.76
LT Debt/Eq	3.60
Option/Short	Yes / Yes

EPS (ttm)	17.24
EPS next Y	24.98
EPS next Q	5.64
EPS this Y	7.60%
EPS next Y	6.29%
EPS next 5Y	7.06%
EPS past 3/5Y	5.51% 2.93%
Sales past 3/5Y	12.09% 7.79%
EPS Y/Y TTM	33.48%
Sales Y/Y TTM	8.60%
EPS Q/Q	19.27%
Sales Q/Q	8.10%
Earnings	Nov 03 AMC
EPS/Sales Surpr.	11.47% 2.95%

Insider Own	0.23%
Insider Trans	-0.81%
Inst Own	85.64%
Inst Trans	-0.35%
ROA	10.09%
ROE	78.35%
ROIC	14.24%
Gross Margin	74.00%
Oper. Margin	35.60%
Profit Margin	24.09%
SMA20	3.36%
SMA50	8.99%
SMA200	21.80%
Trades

Shs Outstand	540.90M
Shs Float	539.68M
Short Float	2.48%
Short Ratio	4.81
Short Interest	13.38M
52W High	483.99 -4.87%
52W Low	312.39 47.39%
Volatility	3.21% 2.55%
ATR (14)	12.80
RSI (14)	60.47
Beta	0.42
Rel Volume	0.93
Avg Volume	2.78M
Volume	2,579,693

Perf Week	-1.20%
Perf Month	13.00%
Perf Quarter	10.36%
Perf Half Y	38.81%
Perf YTD	40.67%
Perf Year	45.89%
Perf 3Y	68.76%
Perf 5Y	115.38%
Perf 10Y	240.04%
Recom	2.68
Target Price	437.32
Prev Close	460.28
Price	460.42
Change %	0.03%

Consensus

Hold

Avg. Price Target

$437.32

Implied Upside

-5.0%

Analysts16incl. previous ratings

Rating Distribution4 Buy · 10 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 08, 2026	Downgrade	BBMO Capital Markets	Outperform → Market Perform	$450	-2.3%
Aug 05, 2026	Reiterated	WWells Fargo	Equal Weight	$390 → $400	-13.1%
Aug 05, 2026	Reiterated	TTruist	Hold	$340 → $362	-21.4%
Aug 05, 2026	Reiterated	RRobert W. Baird	Underperform	$215 → $230	-50.0%
Aug 05, 2026	Reiterated	RRBC Capital Mkts	Outperform	$370 → $400	-13.1%
Aug 05, 2026	Reiterated	OOppenheimer	Outperform	$400 → $450	-2.3%
Aug 05, 2026	Reiterated	MMorgan Stanley	Equal-Weight	$333 → $351	-23.8%
Aug 05, 2026	Reiterated	CCanaccord Genuity	Hold	$366 → $384	-16.6%
Aug 05, 2026	Reiterated	BBofA Securities	Underperform	$312 → $317	-31.1%
Aug 05, 2026	Reiterated	BBMO Capital Markets	Outperform	$400 → $450	-2.3%
May 05, 2026	Downgrade	EErste Group	Buy → Hold
Apr 21, 2026	Initiated	CCanaccord Genuity	Hold	$366	-20.5%
Mar 10, 2026	Initiated	JJefferies	Hold	$350	-24.0%
Feb 20, 2026	Initiated	BBarclays	Equal Weight	$185	-59.8%
Jan 20, 2026	Downgrade	BBernstein	Outperform → Mkt Perform	$335	-27.2%
Jan 07, 2026	Resumed	UUBS	Buy	$380	-17.5%
Dec 05, 2025	Upgrade	EErste Group	Hold → Buy
Nov 24, 2025	Resumed	TTruist	Hold	$318	-30.9%
Nov 13, 2025	Initiated	BScotiabank	Sector Outperform	$385	-16.4%
Sep 03, 2025	Resumed	RRaymond James	Mkt Perform

Nov-06-26 05:35AM	While biotech bets swing on trial data, this dividend payer gained 72% since 2024 (Investing.com)
Nov-05-26 09:00AM	REPATHA LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY (PR Newswire)
Nov-04-26 04:06PM	Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story (PR Newswire)
12:58PM	Amgen earnings analysis: questions answered and next catalysts (Investing.com)
Nov-03-26 07:20PM	Amgen Beats And Raises Again As Imdelltra Data Strengthen The Pipeline, But Growth Is Decelerating Beneath The Headline (Earnings Whispers)
04:40PM	Loading…
04:40PM	Amgen beats third quarter forecasts on top and bottom lines (Investing.com)
04:12PM	Amgen: Q3 Earnings Snapshot (Associated Press)
04:02PM	Amgen, Up 42% This Year, Is Broadly Outperforming Its Peers. Here's What Its Earnings Say. (Investor's Business Daily)
04:01PM	AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS (PR Newswire)
04:29AM	Advanced Micro heads another batch of tech earnings (MarketWatch)
03:30AM	Stock Market Today: Dow, S&P 500 and Nasdaq to decline as U.S. midterm elections loom; AMD results on tap; Apple stock lower after results (MarketWatch)
03:30AM	S&P 500 set for losses ahead of U.S. midterm elections (MarketWatch)
Nov-01-26 10:52PM	Stocktwits Pharma Pulse: Biotech Beats The Broader Market Novo, Pfizer And Moderna Earnings Up Next (Stocktwits)
Oct-30-26 06:51PM	Big Homes, Big Loans (Barrons.com)
08:43AM	AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock (Barrons.com)
04:30PM	Loading…
Oct-28-26 04:30PM	AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS (PR Newswire)
10:21AM	After Wegovy and Zepbound, 6 weight-loss drugs in development (Quartz)
Oct-27-26 04:00PM	AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 (PR Newswire)
01:53PM	Dow Jones Biotech Giant Amgen Breaks Out Ahead Of Q3 Earnings Results (Investor's Business Daily)
Oct-26-26 06:49PM	Amgen Faces Margin Test As Spending Climbs After Two Straight Guidance Raises (Earnings Whispers)
05:52PM	AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS (PR Newswire)
11:58AM	ESMO 26: A cancer vaccine debate, Roches KRAS progress and Amgens unprecedented data (BioPharma Dive)
10:52AM	Moderna's Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show. (Barrons.com)
08:36AM	ESMO26: Key data breathing new life into the lung cancer field (Clinical Trials Arena)
Oct-24-26 10:30AM	IMDELLTRA IN COMBINATION WITH IMFINZI REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER (PR Newswire)
Oct-23-26 08:34AM	At Amgen, Sustainability Is A Companywide Commitment (Investor's Business Daily)
Oct-21-26 06:43AM	Amgen and AstraZeneca report Phase III Tezspire data for EoE (Clinical Trials Arena)
Oct-20-26 05:14PM	Dow outperforms as Wall Street rises, healthcare stocks lead gains (Reuters)
04:15PM	AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 (PR Newswire)
09:00AM	TEZSPIRE DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS (PR Newswire)
12:16PM	Loading…
Oct-19-26 12:16PM	Mattel names second CFO in under 18 months (Retail Dive)
Oct-16-26 10:57PM	What Was Eli Lilly Telling You Before Its Stock Ran? (Trefis)
08:53PM	When Amgen's Forecast And Chart Say The Same Thing, Pay Attention (Trefis)
08:13PM	Is Amgen Stock Increasing Your Market Risk? (Trefis)
03:36PM	Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather (Barrons.com)
03:04PM	9 Dow Jones Stocks Make Bullish Moves In A Defensive Market Rotation (Investor's Business Daily)
Oct-15-26 02:25PM	Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets (MarketWatch)
Oct-14-26 05:45PM	What Could Send Regeneron Stock Higher? (Trefis)
12:00PM	Stocks Struggling With Another Bond Yield Spike (Schaeffer's Research)
11:13AM	Tech stocks take a back seat as healthcare names steal the show (MarketWatch)
09:48AM	Dow rallies 184 points on gains for shares of UnitedHealth, Amgen (MarketWatch)
Oct-13-26 07:48PM	Is Amgen Stock Worth More Than Its Competitors? (Trefis)
03:24PM	What Is Eli Lilly Stock's Biggest Opportunity? (Trefis)
Oct-12-26 08:09AM	Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data (BioPharma Dive)
Oct-09-26 01:11PM	Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact (Clinical Trials Arena)
Oct-08-26 08:19PM	What Is Going On With Regeneron Stock? (Trefis)
10:51AM	Dow's nearly 150-point fall led by losses for shares of Amgen, Johnson & Johnson (MarketWatch)
09:03AM	What Would It Take For Amgen Stock To Move Higher? (Trefis)
Oct-07-26 07:14PM	Is Exelixis Stock Engineered To Make You Money? (Trefis)
04:19PM	Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets (Investopedia)
12:13PM	Why You Should Think About Eli Lilly Stock Differently Now (Trefis)
09:48AM	Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire)
Oct-05-26 10:19AM	Has Eli Lilly Stock Peaked? (Trefis)
Oct-01-26 12:09PM	Walt Disney, Amgen share losses lead Dow's 150-point fall (MarketWatch)
11:41AM	What Is The Options Market Telling Us About Eli Lilly Stock? (Trefis)
Sep-29-26 02:43PM	Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (Trefis)
12:23PM	Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree? (Trefis)
Sep-28-26 08:00AM	KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 (PR Newswire)
Sep-27-26 08:46AM	Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. (Barrons.com)
Sep-25-26 06:00PM	Amgens Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal (The Real Deal)
02:51PM	Dow Stock to Target After Holding Key Support (Schaeffer's Research)
01:13PM	Is LLY Stock Cheaper Than It Looks? (Trefis)
05:30AM	The Peptide Boom That Isn't About Your Muscles (The Wall Street Journal)
Sep-24-26 03:03PM	Can Eli Lilly Stock Catch Up To Rivals It Outgrows? (Trefis)
Sep-23-26 01:54PM	Amgen price target raised by Jefferies to $410 after positive Sjögren's data (Proactive)
08:41AM	Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets (TIKR)
08:35AM	Amgen Stock Gains After Announcing Positive Phase 3 Sjögrens Disease Trial Results (TIKR)
Sep-22-26 04:30PM	Amgen Inc. stock outperforms competitors on strong trading day (MarketWatch)
04:26PM	Amgen Boasts Success In Sjogren's; Shares Charge Ahead (Investor's Business Daily)
02:31PM	Amgen reports a Phase 3 win with Sjögrens drug candidate (BioPharma Dive)
02:04PM	AMGN Jumps After Win In Sjögrens Disease Trial As Citi Flags Open Questions (Stocktwits)
09:00AM	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJOGREN'S DISEASE (PR Newswire)
Sep-21-26 11:55AM	Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (Proactive)
Sep-18-26 05:23PM	What Would It Take For Eli Lilly Stock To Keep Climbing? (Trefis)
04:28PM	Top Research Reports for AMD, Linde & Amgen (Zacks)
Sep-17-26 03:17PM	Can Volume Keep Covering Eli Lilly's Price Cuts? (Trefis)
10:26AM	Amgen Stock Fell 10% in a Day on a Drug It Doesnt Own. Is It Time to Buy AMGN? (TIKR)
Sep-16-26 02:33PM	ALVO Stock Jumps On Double Upgrade Why Barclays Sees A 59% Upside (Stocktwits)
12:33PM	Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It. (Barrons.com)
12:24PM	Why This Biotech Stock Just Got a Rare Double Upgrade (Barrons.com)
Sep-15-26 06:08AM	FDA reduces monitoring time for Amgen's Imdelltra infusions (Pharmaceutical Business Review)
Sep-14-26 04:09PM	Is This LLY Stock Dip Big Enough To Be Worth Buying? (Trefis)
09:00AM	FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA (PR Newswire)
Sep-12-26 05:30AM	Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness (The Wall Street Journal)
Sep-11-26 05:37AM	Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use (BioPharma Dive)
Sep-10-26 11:56AM	Dow's 300-point drop led by losses in shares of NVIDIA Corp., Amgen (MarketWatch)
09:52AM	Meta upgraded, Nvidia initiated: Wall Street's top analyst calls (The Fly)
05:13AM	HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review (Investing.com)
Sep-09-26 10:32PM	Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes (Trefis)
04:41PM	What Eli Lilly Was Telling You While It Rationed Its Own Launches (Trefis)
04:01PM	AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
02:01PM	Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Meets Major Goals (GuruFocus.com)
06:10AM	Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study (InvestorsHub)
Sep-08-26 01:05PM	Amgen, Salesforce share losses contribute to Dow's 525-point fall (MarketWatch) -10.08%
12:35PM	AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test (GuruFocus.com)
12:34PM	Dow Drops, Oil Nears $100 (The Wall Street Journal)
12:07PM	Novartis Trial Failure Sparks Biopharma Options Frenzy (Schaeffer's Research)
10:54AM	Amgen stock's record price plunge is wiping out more than 200 points from the Dow (MarketWatch)
10:46AM	Dow's 650-point drop led by losses for shares of Amgen, Salesforce (MarketWatch)
10:33AM	Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday (Investopedia)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Khosla Rachna	SVP, Business Development	Aug 13 '26	Option Exercise	162.60	1,252	203,575	7,656	Aug 13 07:05 PM
Khosla Rachna	SVP, Business Development	Aug 11 '26	Sale	412.57	2,000	825,134	6,404	Aug 13 07:05 PM
Khosla Rachna	SVP, Business Development	Aug 13 '26	Sale	416.43	1,252	521,365	6,404	Aug 13 07:05 PM
Khosla Rachna	Officer	Aug 13 '26	Proposed Sale	412.76	1,252	516,775		Aug 13 11:14 AM
Khosla Rachna	Officer	Aug 11 '26	Proposed Sale	414.21	2,000	828,420		Aug 11 03:40 PM
Miller Derek	SVP, Human Resources	Aug 06 '26	Option Exercise	169.56	3,890	659,574	14,531	Aug 07 06:47 PM
Miller Derek	SVP, Human Resources	Aug 06 '26	Sale	402.54	3,890	1,565,898	12,462	Aug 07 06:47 PM
Grygiel Nancy A.	SVP & CCO	Aug 06 '26	Option Exercise	177.41	2,970	526,906	9,310	Aug 07 06:45 PM
Grygiel Nancy A.	SVP & CCO	Aug 06 '26	Sale	402.16	2,970	1,194,415	7,340	Aug 07 06:45 PM
Derek Miller	Officer	Aug 06 '26	Proposed Sale	404.85	3,890	1,574,866		Aug 06 05:09 PM
Grygiel Nancy A.	Officer	Aug 06 '26	Proposed Sale	447.17	2,670	1,193,940		Aug 06 02:13 PM
Grygiel Nancy A.	SVP & CCO	May 04 '26	Sale	323.73	1,237	400,451	7,009	May 05 08:09 PM
Grygiel Nancy A.	Officer	May 04 '26	Proposed Sale	323.73	1,237	400,450		May 04 04:05 PM
Bradway Robert A	Chairman, CEO and President	Mar 04 '26	Option Exercise	156.35	119,782	18,727,916	576,928	Mar 06 07:32 PM
Santos Esteban	EVP, Operations	Feb 26 '26	Option Exercise	169.19	54,792	9,270,143	107,119	Mar 02 07:20 PM
Santos Esteban	EVP, Operations	Feb 26 '26	Sale	379.12	54,792	20,772,595	76,618	Mar 02 07:20 PM
Santos Esteban	Associate	Feb 26 '26	Proposed Sale	379.12	54,792	20,772,598		Feb 27 12:20 PM
Busch Matthew C.	VP, Finance & CAO	Feb 19 '26	Sale	375.79	1,000	375,790	3,423	Feb 20 07:43 PM
Busch Matthew C.	ASSOCIATED TO AFFILIATE	Feb 19 '26	Proposed Sale	375.00	1,000	375,000		Feb 19 03:55 PM
Grygiel Nancy A.	SVP & CCO	Nov 20 '25	Option Exercise	169.70	3,139	532,691	8,864	Nov 21 08:34 PM
Grygiel Nancy A.	SVP & CCO	Nov 20 '25	Sale	337.26	3,139	1,058,667	7,225	Nov 21 08:34 PM
Grygiel Nancy A.	Officer	Nov 20 '25	Proposed Sale	337.26	3,139	1,058,667		Nov 20 04:45 PM
Khosla Rachna	SVP, Business Development	Nov 12 '25	Sale	336.24	890	299,256	7,082	Nov 13 07:29 PM
Gordon Murdo	EVP, Global Commercial Ops	Nov 12 '25	Sale	336.83	6,879	2,317,071	41,923	Nov 13 07:28 PM
Gordon Murdo	Officer	Nov 12 '25	Proposed Sale	337.23	6,879	2,319,805		Nov 12 03:02 PM
Khosla Rachna	Officer	Nov 12 '25	Proposed Sale	337.42	890	300,304		Nov 12 02:50 PM

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Chairman & CEOMr. Robert A. Bradway

Executive Vice President of Global Markets and PolicyMr. Murdo Gordon

Executive Vice PresidentMr. Peter H. Griffith

EVP of Research & DevelopmentDr. James E. Bradner M.D.

Executive VP & CFOMr. Thomas J. W. Dittrich

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMGN

AMGEN Inc

Upgrade your Finviz experience